Gould Asset Management LLC CA Invests $445,000 in Boston Scientific Corporation $BSX

Gould Asset Management LLC CA purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,415 shares of the medical equipment provider’s stock, valued at approximately $445,000.

Several other large investors also recently bought and sold shares of BSX. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC boosted its holdings in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its position in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC increased its holdings in shares of Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.1%

Shares of BSX stock opened at $51.77 on Monday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The firm has a market cap of $75.02 billion, a PE ratio of 20.96, a price-to-earnings-growth ratio of 1.13 and a beta of 0.56. The company has a 50-day moving average of $46.06 and a two-hundred day moving average of $59.11. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm earned $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research report on Wednesday, July 29th. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Wells Fargo & Company cut their target price on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. Royal Bank Of Canada reduced their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, Barclays lowered their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 204,322 shares of company stock worth $9,939,221 over the last quarter. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.